Antibodies for
Immunohistochemistry
Androgen Receptor (SP107)
Rabbit Monoclonal Antibody
Cat. No. Description
Volume
45164 IMPATH Androgen Receptor RTU M (SP107)
50 Tests
44199 Androgen Receptor RTU M (SP107)
7 ml Ready To Use
44425 Androgen Receptor 0,1 M (SP107)
100 µl liquid Concentrated
44426 Androgen Receptor 1 M (SP107)
1 ml liquid Concentrated
Product Specifications
Designation
IVD
Reactivity
Paraffin
Visualization
Nuclear
Control
Prostate Carcinoma
Stability
Up to 36 mo. at 2-8°C
Isotype
IgG
Manual Protocol*
• Pretreatment: Heat Induced Epitope
Retrieval (HIER)
• Primary Antibody Incubation Time:
10-30min @ 25-37°C
• 2-step polymer detection
*Please refer to product insert for complete protocol.
ImPath Protocol*
• Dewax: Dewax Solution 2 (DS2)
• Pretreatment: Retrieval Solution pH 9.0
(TR1) 32min @ 98-103°C
• Primary Antibody Incubation Time:
10-90min @ 25-37°C
• HRP Polymer (Universal) or AP Polymer
(Universal) for 12 min
*Please refer to product insert for complete protocol.
Product Description
Anti-androgen receptor has been useful clinically in differentiating morpheaformbasal cell carcinoma (mBCC) from desmoplastic trichoepithelioma
(DTE) in the skin. Immunohistochemical analysis and binding assays have demonstrated the presence of androgen receptors in all histological
types of prostatic carcinoma, both therapy-responsive and therapy-unresponsive. Studies have shown that patients with 48% or more androgen
receptor-positive cells have a statistically significant better outcome in terms of both progression-free and cause-specific survival. The variability
of androgen receptor protein content per unit nuclear area has been shown to increase with increasing histological grade, suggesting that this
variability might account for the response to endocrine therapy in high grade tumors.
Prostate: Malignant vs. Benign
Androgen
Receptor
PSA/PSAP
P504s
CK, 34βE12
p63
CK 5&6
CK 14
Prostate Carcinoma
+
+
+
-
-
-
-
Benign Prostate
+
+
-/+
+
+
+
+
Carcinoma: Differential Diagnosis
Androgen
Receptor
BCA-225
GCDFP-15
ER/PR Mammaglobin PSA/PSAP
CD44
Salivary Duct Carcinoma
+
+
+
-
-
-
-
Breast Carcinoma
+(apocrine)
+
+
+/-
+
-
-
Prostate Carcinoma
+
-
-
-
-
+
+
Cutaneous Neoplasm
Androgen
Receptor
CD10
CK 20
CD34
Ber-EP4
BCL2
CK 19
Basal Cell Carcinoma
+
+
-
-
+
+
+
Trichoepithelioma
-
-
+
+
+
+
+
Merkel Cell Carcinoma
-
-
+
-
+
+
+
Microcystic Adnexal
Carcinoma
-
+/-
-
-
-/+
+
Sebaceous Carcinoma
+
+/-
-
-
+
+/-
-
Reference
1. Bléchet C, et al. Virchows Arch. 2007 Apr; 450(4):433-9. Epub 2007 Feb 28.
2. Carroll RS, et al. Journal Neurosurgery. 1995; 82:453-60.
3. Cordon-Cardo C, et al. J Clin Invest. 2007 Jul; 117(7):1876-83.
26
